Cicaderma® in radiation-related dermatitis of breast cancer: Results from the multicentric randomised phase III CICA-RT

Séverine Racadot; Antoine Arnaud; Camille Schiffler; Séverine Metzger; David Pérol; Youlia Kirova

doi:10.1016/j.ctro.2023.100647

Cicaderma® in radiation-related dermatitis of breast cancer: Results from the multicentric randomised phase III CICA-RT

Clin Transl Radiat Oncol. 2023 Jun 1:41:100647. doi: 10.1016/j.ctro.2023.100647. eCollection 2023 Jul.

Authors

Séverine Racadot¹, Antoine Arnaud², Camille Schiffler³, Séverine Metzger³, David Pérol³, Youlia Kirova⁴

Affiliations

¹ Radiotherapy Department, Centre Léon Bérard, Lyon, France.
² Radiotherapy Department, Institut Sainte-Catherine, Avignon, France.
³ Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France.
⁴ Radiotherapy Department, Institut Curie, Paris, France.

Abstract

Background and purpose: To prevent the occurrence of grade ≥ 2 radiodermatitis after post-operative breast irradiation in patients with non metastatic breast cancer.

Methods: This prospective randomised open-label multicenter study allocated patients from 3 French institutions, ≥18 years, requiring postoperative radiotherapy for histologically proven, early-stage (non-metastatic) unilateral breast adenocarcinoma or in situ breast cancer, with R0 or R1 post-operative status, to receive hygiene rules, associated with either Cicaderma® (Arm A), or preventive treatment according to the investigator preference (mainly hyaluronic acid (ialuset®), essential oils, or water spray, or no medication (Arm B). The primary outcome was to compare the efficacy of Cicaderma® versus local standard management in preventing the occurrence of grade ≥ 2 radiodermatitis. Main secondary objectives include Cicaderma® impact on radiotherapy discontinuation and on skin toxicity (pruritus), pain, quality of life, satisfaction.

Results: The CICA-RT study enrolled from June 2020 to April 2021, 258 women with a median age of 61 (22-91) years in 3 institutions. Patients received either Cicaderma® (A: N = 130) or standard practice (B: N = 128). In the 123 patients who initiated radiotherapy in each arm, 95 (77%, 95%CI 68.8%-84.3%) patients did not develop grade ≥ 2 dermatitis. Sensitivity and per-protocol analyses confirmed the absence of differences between arms.

Conclusion: This prospective study did not meet its primary endpoint of superiority of Cicaderma® over routine practice skin care in terms of prevention of acute radioinduced dermatitis of grade 2 or higher. However, Cicaderma® showed a significant decrease in the occurrence of pruritus with less patients reporting at least once grade ≥ 2 pruritus (A: N = 38, 31%; B: N = 58, 47%; p = 0.009).ClinicalTrials.gov identifier NCT04300829.

Keywords: Breast cancer; Prevention; Radiation Oncology; Radiation dermatitis; Radiation induced skin toxicity; Radiotherapy; Skin care; Topical agents.

Associated data

ClinicalTrials.gov/NCT04300829